-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
We Ran A Stock Scan For Earnings Growth And Guangzhou Kingmed Diagnostics Group (SHSE:603882) Passed With Ease
We Ran A Stock Scan For Earnings Growth And Guangzhou Kingmed Diagnostics Group (SHSE:603882) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.
So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Guangzhou Kingmed Diagnostics Group (SHSE:603882). While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing.
See our latest analysis for Guangzhou Kingmed Diagnostics Group
Guangzhou Kingmed Diagnostics Group's Improving Profits
Over the last three years, Guangzhou Kingmed Diagnostics Group has grown earnings per share (EPS) at as impressive rate from a relatively low point, resulting in a three year percentage growth rate that isn't particularly indicative of expected future performance. So it would be better to isolate the growth rate over the last year for our analysis. Guangzhou Kingmed Diagnostics Group's EPS has risen over the last 12 months, growing from CN¥4.39 to CN¥5.44. That's a 24% gain; respectable growth in the broader scheme of things.
Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. Our analysis has highlighted that Guangzhou Kingmed Diagnostics Group's revenue from operations did not account for all of their revenue in the previous 12 months, so our analysis of its margins might not accurately reflect the underlying business. Guangzhou Kingmed Diagnostics Group maintained stable EBIT margins over the last year, all while growing revenue 39% to CN¥14b. That's encouraging news for the company!
The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.
SHSE:603882 Earnings and Revenue History June 18th 2022Fortunately, we've got access to analyst forecasts of Guangzhou Kingmed Diagnostics Group's future profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting.
Are Guangzhou Kingmed Diagnostics Group Insiders Aligned With All Shareholders?
We would not expect to see insiders owning a large percentage of a CN¥36b company like Guangzhou Kingmed Diagnostics Group. But we do take comfort from the fact that they are investors in the company. Indeed, they have a considerable amount of wealth invested in it, currently valued at CN¥6.0b. Coming in at 17% of the business, that holding gives insiders a lot of influence, and plenty of reason to generate value for shareholders. Very encouraging.
Does Guangzhou Kingmed Diagnostics Group Deserve A Spot On Your Watchlist?
As previously touched on, Guangzhou Kingmed Diagnostics Group is a growing business, which is encouraging. For those who are looking for a little more than this, the high level of insider ownership enhances our enthusiasm for this growth. That combination is very appealing. So yes, we do think the stock is worth keeping an eye on. However, before you get too excited we've discovered 2 warning signs for Guangzhou Kingmed Diagnostics Group (1 shouldn't be ignored!) that you should be aware of.
The beauty of investing is that you can invest in almost any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.
對於初學者來説,收購一家向投資者講述一個好故事的公司似乎是一個好主意(也是一個令人興奮的前景),即使它目前沒有收入和利潤的記錄。不幸的是,這些高風險的投資往往不太可能獲得回報,許多投資者為此付出了代價。雖然一家資金雄厚的公司可能會虧損多年,但它最終需要創造利潤,否則投資者就會離開,公司就會枯萎。
So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Guangzhou Kingmed Diagnostics Group (SHSE:603882). While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing.
因此,如果這種高風險和高回報的想法不適合,你可能會對盈利的、成長型的公司更感興趣,比如廣州金美診斷集團(上交所:603882)。雖然這並不一定意味着它是否被低估了,但該業務的盈利能力足以證明它有一定的升值價值--特別是如果它在增長的話。
See our latest analysis for Guangzhou Kingmed Diagnostics Group
查看我們對廣州金美診斷集團的最新分析
Guangzhou Kingmed Diagnostics Group's Improving Profits
廣州金美德診斷集團利潤不斷提高
Over the last three years, Guangzhou Kingmed Diagnostics Group has grown earnings per share (EPS) at as impressive rate from a relatively low point, resulting in a three year percentage growth rate that isn't particularly indicative of expected future performance. So it would be better to isolate the growth rate over the last year for our analysis. Guangzhou Kingmed Diagnostics Group's EPS has risen over the last 12 months, growing from CN¥4.39 to CN¥5.44. That's a 24% gain; respectable growth in the broader scheme of things.
在過去的三年裏,廣州金美診斷集團的每股收益(EPS)從一個相對較低的水平以同樣驚人的速度增長,導致三年的百分比增長率並不能特別預示未來的預期業績。因此,最好將過去一年的增長率孤立起來,以便我們進行分析。在過去的12個月裏,廣州金美診斷集團的每股收益有所上升,從4.39元增長到5.44元。這是24%的增長;從更廣泛的角度來看,這是一個可觀的增長。
Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. Our analysis has highlighted that Guangzhou Kingmed Diagnostics Group's revenue from operations did not account for all of their revenue in the previous 12 months, so our analysis of its margins might not accurately reflect the underlying business. Guangzhou Kingmed Diagnostics Group maintained stable EBIT margins over the last year, all while growing revenue 39% to CN¥14b. That's encouraging news for the company!
營收增長是一個很好的指標,表明增長是可持續的,再加上高息税前利潤(EBIT)利潤率,這是一家公司在市場上保持競爭優勢的絕佳方式。我們的分析強調,廣州金美診斷集團的收入從運營部未計入其前12個月的全部收入,因此我們對其利潤率的分析可能無法準確反映基礎業務。廣州金美診斷集團去年保持穩定的息税前利潤,同時收入增長39%,達到140億元人民幣。這對公司來説是個鼓舞人心的消息!
The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.
下面的圖表顯示了該公司的利潤和收入是如何隨着時間的推移而變化的。點擊圖表查看確切的數字。
Fortunately, we've got access to analyst forecasts of Guangzhou Kingmed Diagnostics Group's future profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting.
幸運的是,我們已經獲得了廣州金美診斷集團的分析師預測未來利潤。你可以不看就做你自己的預測,或者你可以偷看一下專業人士的預測。
Are Guangzhou Kingmed Diagnostics Group Insiders Aligned With All Shareholders?
廣州金美診斷集團內部人士是否與所有股東一致?
We would not expect to see insiders owning a large percentage of a CN¥36b company like Guangzhou Kingmed Diagnostics Group. But we do take comfort from the fact that they are investors in the company. Indeed, they have a considerable amount of wealth invested in it, currently valued at CN¥6.0b. Coming in at 17% of the business, that holding gives insiders a lot of influence, and plenty of reason to generate value for shareholders. Very encouraging.
我們不希望看到內部人士擁有像廣州金美診斷集團這樣的360億元人民幣公司的很大比例。但我們確實感到欣慰的是,他們是該公司的投資者。事實上,他們有相當數量的財富投資於此,目前價值60億元人民幣。由於持有17%的業務,這種控股給內部人士帶來了很大的影響力,並有足夠的理由為股東創造價值。非常鼓舞人心。
Does Guangzhou Kingmed Diagnostics Group Deserve A Spot On Your Watchlist?
廣州金美診斷集團配得上你的觀察名單嗎?
As previously touched on, Guangzhou Kingmed Diagnostics Group is a growing business, which is encouraging. For those who are looking for a little more than this, the high level of insider ownership enhances our enthusiasm for this growth. That combination is very appealing. So yes, we do think the stock is worth keeping an eye on. However, before you get too excited we've discovered 2 warning signs for Guangzhou Kingmed Diagnostics Group (1 shouldn't be ignored!) that you should be aware of.
正如前面提到的,廣州金美診斷集團是一項不斷增長的業務,這是令人鼓舞的。對於那些希望獲得更多回報的人來説,高水平的內部人持股增強了我們對這一增長的熱情。這種結合非常有吸引力。因此,是的,我們確實認為這隻股票值得關注。然而,在你過於興奮之前,我們已經發現廣州金美診斷集團的2個警示標誌(1不應該被忽視!)這一點你應該知道。
The beauty of investing is that you can invest in almost any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.
投資的美妙之處在於,你幾乎可以投資任何你想投資的公司。但如果你更願意關注那些表現出內幕收購的股票,這裏有一份過去三個月內有內幕收購的公司名單。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
請注意,本文中討論的內幕交易指的是相關司法管轄區內的應報告交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧